Market Trends of Global Pulmonary Drugs Industry
This section covers the major market trends shaping the Pulmonary Drugs Market according to our research experts:
Treatment for Chronic Obstructive Pulmonary Disease is Expected to Witness Growth Over the Forecast Period
Pulmonary drugs like bronchodilators are very common for Chronic Obstructive Pulmonary Disease treatment and symptoms. Bronchodilators are medications that usually come in inhalers. These medications relax the muscles around the patient's airways. This could help relieve coughing and shortness of breath and make breathing easier. Depending on the severity of the patient's disease, the patient may need a short-acting bronchodilator or a long-acting bronchodilator depending on the patient medical condition.
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic lung disease that affects men and women worldwide. According to the World Health Organization (WHO) 2021 factsheet, COPD is the third-leading cause of death worldwide, causing 3.23 million deaths in 2020. Over 80% of these deaths occurred in low- and middle-income countries (LMIC). Moreover, the increasing geriatric population globally is boosting the market growth. According to the World Ageing 2020 report, in 2020, there were around 727 million people aged 65 years or more in the world. The number of older persons is projected to double to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 9.3% in 2020 to reach 16% by 2050. Hence, owing to the fact that asthma is a widely prevalent disease found in people over the age of 65, the growing geriatric population is expected to drive the market growth over the forecast period.
In addition, technological advancements are anticipated to provide the market with lucrative opportunities. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drugs, thereby boosting the market. For instance, in February 2021, Sanofi, in collaboration with Regeneron Pharmaceuticals, initiated a Phase III clinical trial to assess the efficacy and safety of itepekimab on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe chronic obstructive pulmonary disease (COPD). The trial is expected to be completed in July 2024.
The market players are adopting various strategies such as product launches, developments, collaborations, acquisitions, and expansions to increase their market shares. For instance, in July 2020, Novartis AG received approval from the European Commission (EC) for Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide, and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a longacting beta2agonist (LABA) and a high-dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year. Thus, the aforementioned factors are boosting the growth of the market.
North America Dominates the Market and Expected to do Same in the Forecast Period
The increasing prevalence of respiratory diseases is the major factor expected to drive the overall growth of the market over the forecast period. Also, there is a rise in per capita health expenditure in the region, which is expected to increase over the forecast period, owing to the decrease in the unemployment rate. The cases of COPD are likely to increase in the United States, owing to the higher smoking prevalence and the aging population in the country.
In the United States, asthma is more common in adult women than in adult men. According to the Centers for Disease Control and Prevention 2021 report, in the United States, approximately 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8% of adults and 7% of children. About 20 million US adults aged 18 years and over have asthma.
Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC's National Asthma Control Program (NACP) provides funds for educating asthma-affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of drugs in the treatment of asthma, leading to verticle growth.
In addition, the local presence of key pharmaceutical players, advanced healthcare infrastructure, and increasing research and development activities in the development of novel therapies are boosting the market growth. For instance, in March 2021, in Mexico and the United States, AstraZeneca PLC started a Phase III clinical trial to assess the efficacy and safety of budesonide/glycopyrronium/formoterol inhalers in adults and adolescents with severe asthma inadequately controlled with the standard of care. The trial is expected to be completed in September 2023. In July 2021, AstraZeneca's Biologics License Application (BLA) for tezepelumab was accepted and granted Priority Review for the treatment of asthma by the United States Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen Inc. Thus, the aforementioned factors are expected to drive the market growth over the forecast period.
